NFATC2 and melanoma: Targeting NFATc2 by si/shRNA or by an inhibitor known to downregulate EMT-related markers inhibited the migratory and invasive capacity of melanoma cells in vitro and in vivo, which is caused by an altered expression of downstream molecules thereby reversing the EMT-like program.